{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:17Z","timestamp":1788998417057,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Identifying the optimal fremanezumab treatment strategy is crucial in treating patients with migraines. The optimal strategy was investigated by assessing the cumulative 50% reduction rate (50%CRR), cumulative 75% reduction rate (75%CRR), reduction in the number of migraine days, treatment-related adverse events, and serious adverse events in patients treated with fremanezumab 225\u00a0mg monthly (225\u00a0mg), 675\u00a0mg monthly (675\u00a0mg), 900\u00a0mg monthly (900\u00a0mg), a single high dose of 675\u00a0mg (S675mg), 675\u00a0mg at baseline with 225\u00a0mg monthly (675\/225\u00a0mg), and placebo. Biomedical databases were searched for randomized controlled trials on this topic, and data were individually extracted. Risk ratios and mean differences were used to present the pooled results. The surface under the cumulative ranking curve (SUCRA) was used to determine the effects of the medication strategies of fremanezumab. Five trials (n\u2009=\u20093404) were used to form a six-node network meta-analysis. All fremanezumab medication strategies displayed significantly higher cumulative 50% reduction rates than the placebo. The SUCRA revealed that treatment with 675\u00a0mg yielded the highest 50%CRR value (mean rank\u2009=\u20092.5). S675 mg was the only treatment with significantly higher 75%CRR reduction rate than placebo, whereas the SUCRA for 225\u00a0mg displayed the highest mean rank (2.2). Moreover, 225\u00a0mg (mean rank\u2009=\u20092.2) and S675 mg (mean rank\u2009=\u20092.2) presented lower probabilities of serious adverse events. Collectively, S675mg and 225\u00a0mg exhibited the optimal balance between efficacy and safety within three months. Long-term efficacy and safety remain unclear, and future studies should further evaluate the long-term outcomes.<\/jats:p>","DOI":"10.1038\/s41598-020-75602-8","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T11:02:54Z","timestamp":1603969374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimal treatment strategy of fremanezumab in migraine prevention: a systematic review with network meta-analysis of randomized clinical trials"],"prefix":"10.1038","volume":"10","author":[{"given":"I-Hsin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-No","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"75602_CR1","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/head.13382","volume":"58","author":"J Lai","year":"2018","unstructured":"Lai, J., Harrison, R. A., Plecash, A. & Field, T. S. A narrative review of persistent post-stroke headache: a new entry in the international classification of headache disorders. Headache 58, 1442\u20131453. https:\/\/doi.org\/10.1111\/head.13382 (2018).","journal-title":"Headache"},{"key":"75602_CR2","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1523\/JNEUROSCI.0373-15.2015","volume":"35","author":"R Burstein","year":"2015","unstructured":"Burstein, R., Noseda, R. & Borsook, D. Migraine: multiple processes, complex pathophysiology. J. Neurosci. 35, 6619\u20136629. https:\/\/doi.org\/10.1523\/JNEUROSCI.0373-15.2015 (2015).","journal-title":"J. Neurosci."},{"key":"75602_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41582-019-0134-z","volume":"15","author":"C Tassorelli","year":"2019","unstructured":"Tassorelli, C. & De Icco, R. Getting closer to a cure for migraine. Nat. Rev. Neurol. 15, 64\u201365. https:\/\/doi.org\/10.1038\/s41582-019-0134-z (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"75602_CR4","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s40263-018-0579-4","volume":"32","author":"ME Bigal","year":"2018","unstructured":"Bigal, M. E. et al. From LBR-101 to fremanezumab for migraine. CNS Drugs 32, 1025\u20131037. https:\/\/doi.org\/10.1007\/s40263-018-0579-4 (2018).","journal-title":"CNS Drugs"},{"key":"75602_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","volume":"55","author":"AF Russo","year":"2015","unstructured":"Russo, A. F. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu. Rev. Pharmacol. Toxicol. 55, 533\u2013552. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010814-124701 (2015).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"75602_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson, L., Haanes, K. A., Warfvinge, K. & Krause, D. N. CGRP as the target of new migraine therapies: successful translation from bench to clinic. Nat. Rev. Neurol. 14, 338\u2013350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"75602_CR7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/head.12642","volume":"55","author":"S Silberstein","year":"2015","unstructured":"Silberstein, S., Lenz, R. & Xu, C. Therapeutic monoclonal antibodies: what headache specialists need to know. Headache 55, 1171\u20131182. https:\/\/doi.org\/10.1111\/head.12642 (2015).","journal-title":"Headache"},{"key":"75602_CR8","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1111\/bcp.14096","volume":"85","author":"JB Fiedler-Kelly","year":"2019","unstructured":"Fiedler-Kelly, J. B. et al. Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine. Br. J. Clin. Pharmacol. 85, 2721\u20132733. https:\/\/doi.org\/10.1111\/bcp.14096 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"75602_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/s1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal, M. E. et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 14, 1091\u20131100. https:\/\/doi.org\/10.1016\/s1474-4422(15)00245-8 (2015).","journal-title":"Lancet Neurol."},{"key":"75602_CR10","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick, D. W. et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 13, 1100\u20131107. https:\/\/doi.org\/10.1016\/S1474-4422(14)70209-1 (2014).","journal-title":"Lancet Neurol."},{"key":"75602_CR11","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby, P. J. et al. A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 377, 2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848 (2017).","journal-title":"N. Engl. J. Med."},{"key":"75602_CR12","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1177\/0333102417747230","volume":"38","author":"TMM Oakes","year":"2018","unstructured":"Oakes, T. M. M. et al. Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study. Cephalalgia 38, 1015\u20131025. https:\/\/doi.org\/10.1177\/0333102417747230 (2018).","journal-title":"Cephalalgia"},{"key":"75602_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun, H. et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 15, 382\u2013390. https:\/\/doi.org\/10.1016\/S1474-4422(16)00019-3 (2016).","journal-title":"Lancet Neurol."},{"key":"75602_CR14","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/0333102419840780","volume":"39","author":"W Kielbasa","year":"2019","unstructured":"Kielbasa, W. & Helton, D. L. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia 39, 1284\u20131297. https:\/\/doi.org\/10.1177\/0333102419840780 (2019).","journal-title":"Cephalalgia"},{"key":"75602_CR15","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.2147\/JPR.S166427","volume":"12","author":"J Robblee","year":"2019","unstructured":"Robblee, J. & VanderPluym, J. Fremanezumab in the treatment of migraines: evidence to date. J. Pain Res. 12, 2589\u20132595. https:\/\/doi.org\/10.2147\/JPR.S166427 (2019).","journal-title":"J. Pain Res."},{"key":"75602_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143527","author":"IH Huang","year":"2019","unstructured":"Huang, I. H., Wu, P. C., Lin, E. Y., Chen, C. Y. & Kang, Y. N. Effects of anti-calcitonin gene-related peptide for migraines: a systematic review with meta-analysis of randomized clinical trials. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20143527 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"75602_CR17","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s10072-018-3547-3","volume":"39","author":"Y Zhu","year":"2018","unstructured":"Zhu, Y. et al. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol. Sci. 39, 2097\u20132106. https:\/\/doi.org\/10.1007\/s10072-018-3547-3 (2018).","journal-title":"Neurol. Sci."},{"key":"75602_CR18","doi-asserted-by":"publisher","first-page":"e01215","DOI":"10.1002\/brb3.1215","volume":"9","author":"L Han","year":"2019","unstructured":"Han, L., Liu, Y., Xiong, H. & Hong, P. CGRP monoclonal antibody for preventive treatment of chronic migraine: an update of meta-analysis. Brain Behav. 9, e01215. https:\/\/doi.org\/10.1002\/brb3.1215 (2019).","journal-title":"Brain Behav."},{"key":"75602_CR19","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1177\/0333102419829007","volume":"39","author":"D Xu","year":"2019","unstructured":"Xu, D. et al. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine: a meta-analysis of randomized controlled trials. Cephalalgia 39, 1164\u20131179. https:\/\/doi.org\/10.1177\/0333102419829007 (2019).","journal-title":"Cephalalgia"},{"key":"75602_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/head.13740","volume":"60","author":"YH Lee","year":"2020","unstructured":"Lee, Y. H., Huang, I. H. & Kang, Y. N. Do treatment strategies of fremanezumab have similar effect on migraine?. Headache 60, 473\u2013475. https:\/\/doi.org\/10.1111\/head.13740 (2020).","journal-title":"Headache"},{"key":"75602_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1212\/wnl.0000000000002801","volume":"87","author":"ME Bigal","year":"2016","unstructured":"Bigal, M. E. et al. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology 87, 41\u201348. https:\/\/doi.org\/10.1212\/wnl.0000000000002801 (2016).","journal-title":"Neurology"},{"key":"75602_CR22","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/head.13156","volume":"57","author":"JM Cohen","year":"2017","unstructured":"Cohen, J. M. et al. Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines. Headache 57, 1375\u20131384. https:\/\/doi.org\/10.1111\/head.13156 (2017).","journal-title":"Headache"},{"key":"75602_CR23","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick, D. W. et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319, 1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853 (2018).","journal-title":"JAMA"},{"key":"75602_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/head.13446","volume":"59","author":"SD Silberstein","year":"2019","unstructured":"Silberstein, S. D. et al. The effect of beginning treatment with fremanezumab on headache and associated symptoms in the randomized phase 2 study of high frequency episodic migraine: post-hoc analyses on the first 3 weeks of treatment. Headache 59, 383\u2013393. https:\/\/doi.org\/10.1111\/head.13446 (2019).","journal-title":"Headache"},{"key":"75602_CR25","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein, S. D. et al. Fremanezumab for the preventive treatment of chronic migraine. N. Engl. J. Med. 377, 2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038 (2017).","journal-title":"N. Engl. J. Med."},{"key":"75602_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0333102418772585","volume":"39","author":"RB Halker Singh","year":"2019","unstructured":"Halker Singh, R. B. et al. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: post-hoc analyses from phase 2 trials. Cephalalgia 39, 52\u201360. https:\/\/doi.org\/10.1177\/0333102418772585 (2019).","journal-title":"Cephalalgia"},{"key":"75602_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31946-4","author":"MD Ferrari","year":"2019","unstructured":"Ferrari, M. D. et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet https:\/\/doi.org\/10.1016\/s0140-6736(19)31946-4 (2019).","journal-title":"Lancet"},{"key":"75602_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/head.13534","volume":"59","author":"SD Silberstein","year":"2019","unstructured":"Silberstein, S. D. et al. Safety and tolerability of fremanezumab for the prevention of migraine: a pooled analysis of phases 2b and 3 clinical trials. Headache 59, 880\u2013890. https:\/\/doi.org\/10.1111\/head.13534 (2019).","journal-title":"Headache"},{"key":"75602_CR29","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/head.13654","volume":"59","author":"PK Winner","year":"2019","unstructured":"Winner, P. K. et al. Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. Headache 59, 1743\u20131752. https:\/\/doi.org\/10.1111\/head.13654 (2019).","journal-title":"Headache"},{"key":"75602_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419885905","author":"JL Brandes","year":"2019","unstructured":"Brandes, J. L. et al. Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine. Cephalalgia https:\/\/doi.org\/10.1177\/0333102419885905 (2019).","journal-title":"Cephalalgia"},{"key":"75602_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp, Z., Bloudek, L. M. & Varon, S. F. Systematic review of migraine prophylaxis adherence and persistence. J. Manag. Care Pharm. 20, 22\u201333. https:\/\/doi.org\/10.18553\/jmcp.2014.20.1.22 (2014).","journal-title":"J. Manag. Care Pharm."},{"key":"75602_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","volume":"79","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi, S. et al. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs 79, 417\u2013431. https:\/\/doi.org\/10.1007\/s40265-019-01069-1 (2019).","journal-title":"Drugs"},{"key":"75602_CR33","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s40265-018-1004-5","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy, S. M. Fremanezumab: first global approval. Drugs 78, 1829\u20131834. https:\/\/doi.org\/10.1007\/s40265-018-1004-5 (2018).","journal-title":"Drugs"},{"key":"75602_CR34","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/head.13439","volume":"58","author":"M Levin","year":"2018","unstructured":"Levin, M. et al. Basic considerations for the use of monoclonal antibodies in migraine. Headache 58, 1689\u20131696. https:\/\/doi.org\/10.1111\/head.13439 (2018).","journal-title":"Headache"},{"key":"75602_CR35","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2147\/ndt.s3497","volume":"4","author":"D D'Amico","year":"2008","unstructured":"D\u2019Amico, D. & Tepper, S. J. Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr. Dis. Treat. 4, 1155\u20131167. https:\/\/doi.org\/10.2147\/ndt.s3497 (2008).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"75602_CR36","doi-asserted-by":"publisher","unstructured":"DALYs, G. B. D. & Collaborators, H. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1859\u20131922. https:\/\/doi.org\/10.1016\/S0140-6736(18)32335-3 (2018).","DOI":"10.1016\/S0140-6736(18)32335-3"},{"key":"75602_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s10194-017-0750-1","volume":"18","author":"M Hou","year":"2017","unstructured":"Hou, M. et al. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J. Headache Pain 18, 42. https:\/\/doi.org\/10.1186\/s10194-017-0750-1 (2017).","journal-title":"J. Headache Pain"},{"key":"75602_CR38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.yrtph.2019.05.013","volume":"106","author":"JL Bussiere","year":"2019","unstructured":"Bussiere, J. L. et al. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul. Toxicol. Pharmacol. 106, 224\u2013238. https:\/\/doi.org\/10.1016\/j.yrtph.2019.05.013 (2019).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"75602_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/head.13064","volume":"57","author":"DL Hay","year":"2017","unstructured":"Hay, D. L. & Walker, C. S. CGRP and its receptors. Headache 57, 625\u2013636. https:\/\/doi.org\/10.1111\/head.13064 (2017).","journal-title":"Headache"},{"key":"75602_CR40","unstructured":"Sun, H., Gavva, N. & Xu, C. In 57th Annual Scientific Meeting of the American Headache Society (Washington, DC, 2015)."},{"key":"75602_CR41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton, B. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med. 162, 777\u2013784. https:\/\/doi.org\/10.7326\/m14-2385 (2015).","journal-title":"Ann. Intern. Med."},{"key":"75602_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JP Higgins","year":"2019","unstructured":"Higgins, J. P. et al. Cochrane Handbook for Systematic Reviews of Interventions (Wiley, Hoboken, 2019)."},{"key":"75602_CR43","doi-asserted-by":"publisher","first-page":"e2019013","DOI":"10.4178\/epih.e2019013","volume":"41","author":"SR Shim","year":"2019","unstructured":"Shim, S. R., Kim, S. J., Lee, J. & R\u00fccker, G. Network meta-analysis: application and practice using R software. Epidemiol. Health 41, e2019013. https:\/\/doi.org\/10.4178\/epih.e2019013 (2019).","journal-title":"Epidemiol. Health"},{"key":"75602_CR44","unstructured":"Sadeghirad, B., Brignardello-Petersen, R., Johnston, B., Guyatt, G. & Beyene, J. Comparing Bayesian and Frequentist Approaches for Network Meta-Analysis: An Empirical Study. Global Evidence Summit, Cape Town, South Africa. Cochrane Database Syst. Rev. 9 https:\/\/abstracts.cochrane.org\/2017-global-evidence-summit\/comparing-bayesian-and-frequentist-approaches-network-meta-analysis (2017)."},{"key":"75602_CR45","volume-title":"Network Meta-analysis in R","author":"M Harrer","year":"2019","unstructured":"Harrer, M., Cuijpers, P., Furukawa, T. & Ebert, D. In Network Meta-analysis in R (ed. Ebert, D. D.) (PROTECT Lab, Erlangen, 2019)."},{"key":"75602_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/jrsm.1050","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti, G. & Schmid, C. H. Research synthesis methods special issue on network meta-analysis: introduction from the editors. Res. Synth. Methods 3, 69\u201370. https:\/\/doi.org\/10.1002\/jrsm.1050 (2012).","journal-title":"Res. Synth. Methods"},{"key":"75602_CR47","volume-title":"Users\u2019 Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice","author":"G Gordon","year":"2014","unstructured":"Gordon, G., Drummond, R., Maureen, O. & Deborah, J. Users\u2019 Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice (McGraw-Hill Education, New York, 2014)."},{"key":"75602_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse, B., Chaimani, A. & Li, T. Network meta-analysis: an introduction for clinicians. Intern. Emerg. Med. 12, 103\u2013111. https:\/\/doi.org\/10.1007\/s11739-016-1583-7 (2017).","journal-title":"Intern. Emerg. Med."},{"key":"75602_CR49","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1177\/1536867X1501500402","volume":"15","author":"A Chaimani","year":"2015","unstructured":"Chaimani, A. & Salanti, G. Visualizing assumptions and results in network meta-analysis: the network graphs package. Stata J. 15, 905\u2013950 (2015).","journal-title":"Stata J."},{"key":"75602_CR50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","volume":"6","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw, L. et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst. Rev. 6, 79. https:\/\/doi.org\/10.1186\/s13643-017-0473-z (2017).","journal-title":"Syst. Rev."},{"key":"75602_CR51","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P. & Salanti, G. Graphical tools for network meta-analysis in STATA. PLoS ONE 8, e76654\u2013e76654. https:\/\/doi.org\/10.1371\/journal.pone.0076654 (2013).","journal-title":"PLoS ONE"},{"key":"75602_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/head.13446","author":"SD Silberstein","year":"2018","unstructured":"Silberstein, S. D. et al. The effect of beginning treatment with fremanezumab on headache and associated symptoms in the randomized phase 2 study of high frequency episodic migraine: post-hoc analyses on the first 3 weeks of treatment. Headache https:\/\/doi.org\/10.1111\/head.13446 (2018).","journal-title":"Headache"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75602-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75602-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75602-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T22:28:03Z","timestamp":1670365683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75602-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["75602"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-75602-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"1 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18609"}}